(Q42795564)

English

Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation

scientific article published on November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 November 2017

Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation (English)

1 reference

Europe PubMed Central

7 November 2017

immunosuppression

1 reference

based on heuristic

inferred from title

author name string

G Ciancio

1

1 reference

Europe PubMed Central

7 November 2017

J J Gaynor

2

1 reference

Europe PubMed Central

7 November 2017

D Roth

3

1 reference

Europe PubMed Central

7 November 2017

W Kupin

4

1 reference

Europe PubMed Central

7 November 2017

L Hanson

5

1 reference

Europe PubMed Central

7 November 2017

L Tueros

6

1 reference

Europe PubMed Central

7 November 2017

A Zarak

7

1 reference

Europe PubMed Central

7 November 2017

P Ruiz

8

1 reference

Europe PubMed Central

7 November 2017

G W Burke

9

1 reference

Europe PubMed Central

7 November 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

7 November 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

7 November 2017

42

1 reference

Europe PubMed Central

7 November 2017

9

1 reference

Europe PubMed Central

7 November 2017

3503-3506

1 reference

Europe PubMed Central

7 November 2017

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Long-term immunosuppression, without maintenance prednisone, after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.08.045

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2010.08.045

1 reference

Europe PubMed Central

7 November 2017

1 reference

Europe PubMed Central

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42795564&oldid=1970575342"